Ipratropium Bromide

一到换季就喷嚏不断、鼻塞眼痒？皮肤反复泛红起疹，药膏涂了又停？过敏原查不出、躲不开，过敏成了“慢性病”？别再让过敏折磨你和家人。 今天这篇，把目前医学对付过敏的最高阶方案讲透，照着做，少走弯路、少遭罪。过敏性疾病，早已被定义为慢性病。 它不是“忍忍就好”的小毛病，发作时难受，缓解时潜伏，一有风吹草动就卷土重来。 长期反复的炎症，还可能从鼻炎拖成哮喘，从小皮疹拖成顽固皮炎，甚至带来焦虑、睡眠差等连锁反应。 好消息是，现代医学对过敏已经有成熟、有效、可落地的整套方案。 世界卫生组织（WHO）更是明确提出过敏治疗“四位一体”，写进全球指南：患者教育、过敏原隔绝、对症药物治疗、免疫治疗前面我们讲过如何避开过敏原，今天重点讲：药怎么用才对、什么情况能“治本”、日常如何降低发作。 看完这篇，你就是自己的“家庭过敏管理师”。一、对症用药：别踩3个致命误区过敏一线用药就这几类，医院常开、很多也是非处方药，但80%的人都用错了。误区1：激素副作用超大，能不用就不用这是最常见的恐惧。 冯雪医生在门诊里，每次开外用激素都要反复解释——外用激素，没你想的那么可怕。不管是过敏性鼻炎用的布地奈德、糠酸莫米松鼻喷剂，还是皮炎用的激素软膏，多国临床研究证实： 连续使用1年以上，不影响儿童生长发育，不降低局部免疫力，不增加感染风险。它是全球指南首推一线药，效果明确、安全性高。只有它无效，才考虑换方案。 千万别因为“怕激素”，把炎症拖成大病。误区2：症状一消失，立刻停药鼻炎不堵了、不痒了，马上停喷、停药？ 这是复发之王。过敏症状消失，不代表炎症消失。 黏膜仍有低度炎症，免疫系统也没完全稳定，此时停药，等于“给敌人留后门”。正确用法：• 轻度/间歇性过敏：用药至少2周• 中重度/持续性过敏：用药至少4周• 稳定后可用最低剂量维持，比断断续续好太多误区3：药不管用就硬扛按要求用了仍不好，别放弃，医生还有后手：• 黏膜水肿重 → 加用抗白三烯药（孟鲁司特）• 打喷嚏、痒明显 → 联用抗组胺药（氯雷他定、西替利嗪）• 鼻塞严重 → 短期用减充血剂（3–5天）• 水样涕不止 → 加用异丙托溴铵严重过敏，还有生物制剂（如奥马珠单抗），精准靶向、副作用小，对重度季节性过敏、哮喘效果显著。二、免疫治疗：过敏界的“治本”方案用药仍控制不佳？还有终极武器——免疫疗法。它不是“压制症状”，而是训练免疫系统：在医生指导下，小剂量、多次、逐渐加量接触过敏原（皮下注射/舌下含服），让身体从“过激”变成“耐受”，最终实现脱敏。效果很硬核：• 对过敏性鼻炎、哮喘、结膜炎有效• 降低新发过敏风险，减少发展成哮喘的概率• 疗效可持续长达7年 适合人群：• 能明确单一过敏原• 常规药物效果不好• 愿意坚持疗程（通常3年左右）三、日常这样做，从根源减少过敏过敏的本质，是免疫系统波动。睡眠、压力、体重、运动、饮食、环境，都在悄悄影响它。这些被医学证实的建议，坚持做，过敏会越来越轻：• 规律有氧运动，优先游泳：增强免疫、减少鼻炎发作• 控制体重：超重/肥胖会升高湿疹、鼻炎、哮喘风险• 强化皮肤屏障：湿疹宝宝/成人，大量涂保湿霜• 减压+睡够：压力直接加重过敏反复• 远离烟、雾霾、PM2.5：降低哮喘与过敏发作• 饮食多样化：稳定肠道菌群，筑牢免疫防线• 准妈妈建议：均衡饮食，优先母乳喂养，辅食5–7个月合理添加关于保健品：• 益生菌/益生元：对鼻炎、哮喘无明确预防作用，不必额外补• 维生素D：证据不足• Omega-3：孕期补充，或可降低孩子过敏风险最后总结过敏不可怕，可怕的是用错方法、反复拖延。牢牢记住WHO“四位一体”：懂知识、避过敏原、用对药、必要时脱敏，再配合健康生活，你就站在了对抗过敏的医学高点。下次发作时，别揉鼻子、别抓皮肤、别硬扛。科学管理，过敏真的可以越来越少、越来越轻。

Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026. "In the first quarter of 2026, we continued to strengthen our commercial foundation and core business, highlighted by the approval and subsequent launch of Ipratropium Bromide HFA, while also making meaningful advancements across our pipeline that will support our long‑term strategy," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "To begin the year, we broadened our portfolio through an exclusive license agreement for a fully synthetic corticotropin compound. At the same time, we remain committed to investing in our proprietary pipeline and capabilities, which we believe will support sustainable long-term growth." Three Months Ended March 31, 2026 2025 (in thousands, except per share data) Net revenues $ 171,171 $ 170,528 GAAP net income $ 6,420 $ 25,285 Adjusted non-GAAP net income* $ 19,478 $ 36,871 GAAP diluted EPS $ 0.14 $ 0.51 Adjusted non-GAAP diluted EPS* $ 0.42 $ 0.74 ________________________________ * Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release. First Quarter Results Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Net revenues: BAQSIMI ® $ 32,434 $ 38,355 $ (5,921 ) (15 )% Primatene MIST ® 29,763 29,051 712 2 % Epinephrine 19,213 18,587 626 3 % Lidocaine 13,460 13,644 (184 ) (1 )% Glucagon 9,170 20,843 (11,673 ) (56 )% Other products 67,131 50,048 17,083 34 % Total net revenues $ 171,171 $ 170,528 $ 643 0 % Changes in net revenues as compared to the first quarter of the prior year were primarily driven by: BAQSIMI ® sales decreased primarily due to a lower average selling price, as a result of a change in gross-to-net discounts due to changes in chargebacks and rebates and changes to the customer mix, impacting sales of approximately $8.0 million. This decrease was partially offset by an increase in unit volumes, contributing $2.0 million in sales driven by our continued marketing efforts Primatene MIST ® sales increased due to an increase in unit volumes Epinephrine sales increased primarily due to an increase in demand for our epinephrine pre-filled syringe, as a result of other supplier shortages, contributing $4.1 million in sales. This increase was partially offset by a decrease in our epinephrine multi-dose vial product, as a result of increased competition, impacting sales by $3.5 million Glucagon sales decreased primarily due to a decrease in unit volumes, impacting sales by $6.1 million, as well as a lower average selling price, which impacted sales by $5.6 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI ® Other pharmaceutical product sales increased primarily due to recently launched products including an increase in albuterol sales of $2.8 million, iron sucrose sales of $1.4 million and teriparatide sales of $2.2 million, which we launched in August 2024, August 2025, and December 2025, respectively. An increase in dextrose sales, driven by heightened demand resulting from supplier shortages in the market also positively impacted sales Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Net revenues $ 171,171 $ 170,528 $ 643 0 % Cost of revenues 100,849 85,277 15,572 18 % Gross profit $ 70,322 $ 85,251 $ (14,929 ) (18 )% as % of net revenues 41.1 % 50.0 % Changes in the cost of revenues and gross margin were primarily driven by: Lower average selling price for our higher margin products, such as BAQSIMI ® , glucagon, phytonadione, and our epinephrine multi-dose vial product Increased manufacturing expenses due to the expansion of our manufacturing facility in Rancho Cucamonga, CA Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Selling, distribution, and marketing $ 11,927 $ 11,866 $ 61 1 % General and administrative 18,028 15,996 2,032 13 % Research and development 26,737 20,096 6,641 33 % General and administrative expenses increased primarily due to an increase in legal expenses, expenses associated with implementing a new ERP system and salary and personnel-related expenses Research and development expenses increased primarily due to spending for our insulin, inhalation, and proprietary pipeline products. Additionally, we had a $2.0 million upfront payment for the licensing agreement that we entered into with Nanjing Hanxin Pharmaceutical Technology Co., Ltd., during the quarter Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Non-operating expenses: Interest income $ 2,400 $ 2,089 $ 311 15 % Interest expense (6,553 ) (6,286 ) (267 ) 4 % Other income (expenses), net 575 (2,234 ) 2,809 (126 )% Total non-operating expenses, net $ (3,578 ) $ (6,431 ) $ 2,853 (44 )% The change in non-operating expenses, net, is primarily a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended March 31, 2026. Cash flow provided by operating activities for the three months ended March 31, 2026, was $47.8 million. Pipeline Information The Company currently has one abbreviated new drug application ("ANDA") and one biosimilar insulin candidate filed with the FDA targeting products with a combined market size exceeding $1.6 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $0.8 billion. This market information is based on IQVIA data for the 12 months ended March 31, 2026. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms. The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions. Conference Call Information The Company will hold a conference call to discuss its financial results today, May 7, 2026, at 2:00 p.m. Pacific Time. To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference. The call can also be accessed on the Investors page on the Company's website, . Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Market Data This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections. About Amphastar Pharmaceuticals, Inc. Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at . Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ® , BAQSIMI ® , Primatene MIST ® , REXTOVY ® , Amphadase ® , and Cortrosyn ® , are the property of Amphastar. Forward Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, and our other filings or reports that we may the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI ® . You can locate these reports through our website at and on the SEC's website at . The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact Information: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 476-3416 Table I Amphastar Pharmaceuticals, Inc. Condensed Consolidated Statement of Operations (Unaudited; in thousands, except per share data) Three Months Ended March 31, 2026 2025 Net revenues $ 171,171 $ 170,528 Cost of revenues 100,849 85,277 Gross profit 70,322 85,251 Operating expenses: Selling, distribution, and marketing 11,927 11,866 General and administrative 18,028 15,996 Research and development 26,737 20,096 Total operating expenses 56,692 47,958 Income from operations 13,630 37,293 Non-operating expenses: Interest income 2,400 2,089 Interest expense (6,553 ) (6,286 ) Other income (expenses), net 575 (2,234 ) Total non-operating expenses, net (3,578 ) (6,431 ) Income before income taxes 10,052 30,862 Income tax provision 3,632 5,577 Net income $ 6,420 $ 25,285 Net income per share: Basic $ 0.14 $ 0.53 Diluted $ 0.14 $ 0.51 Weighted-average shares used to compute net income per share: Basic 45,322 47,641 Diluted 46,458 49,890 Table II Amphastar Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except per share data) March 31, December 31, 2026 2025 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 170,939 $ 170,177 Restricted cash 235 235 Short-term investments 121,012 112,635 Restricted short-term investments 2,200 2,200 Accounts receivable, net 147,848 143,560 Inventories 170,194 176,890 Income tax refunds and deposits 9,605 17,167 Prepaid expenses and other assets 11,650 13,152 Total current assets 633,683 636,016 Property, plant, and equipment, net 307,231 310,567 Finance lease right-of-use assets 185 221 Operating lease right-of-use assets 71,496 42,931 Goodwill and intangible assets, net 559,623 565,965 Other assets 33,480 31,135 Deferred tax assets 42,464 42,464 Total assets $ 1,648,162 $ 1,629,299 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 152,688 $ 148,348 Income taxes payable 414 239 Current portion of long-term debt 1,671 1,641 Current portion of operating lease liabilities 9,705 7,928 Total current liabilities 164,478 158,156 Long-term reserve for income tax liabilities 5,926 5,926 Long-term debt, net of current portion and unamortized debt issuance costs 609,801 608,749 Long-term operating lease liabilities, net of current portion 65,201 37,684 Other long-term liabilities 29,365 29,979 Total liabilities 874,771 840,494 Commitments and contingencies Stockholders' equity: Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding - - Common stock: par value $0.0001; 300,000,000 shares authorized; 62,134,449 and 44,636,846 shares issued and outstanding, respectively, as of March 31, 2026 and 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 6 6 Additional paid-in capital 543,816 535,380 Retained earnings 673,301 666,881 Accumulated other comprehensive loss (5,736 ) (5,314 ) Treasury stock (437,996 ) (408,148 ) Total stockholders' equity 773,391 788,805 Total liabilities and stockholders' equity $ 1,648,162 $ 1,629,299 Table III Amphastar Pharmaceuticals, Inc. Reconciliation of Non-GAAP Measures (Unaudited; in thousands, except per share data) Three Months Ended March 31, 2026 2025 GAAP net income $ 6,420 $ 25,285 Adjusted for: Intangible asset amortization 6,270 6,240 Share-based compensation 9,274 8,393 Litigation provision 1,000 - Income tax provision on pre-tax adjustments (3,486 ) (3,047 ) Adjusted non-GAAP net income $ 19,478 $ 36,871 Adjusted non-GAAP net income per share: Basic $ 0.43 $ 0.77 Diluted $ 0.42 $ 0.74 Weighted-average shares used to compute adjusted non-GAAP net income per share: Basic 45,322 47,641 Diluted 46,458 49,890 Three Months Ended March 31, 2026 Selling, General Research Cost of distribution and and Income revenue and marketing administrative development tax provision GAAP $ 100,849 $ 11,927 $ 18,028 $ 26,737 $ 3,632 Intangible asset amortization (6,250 ) - (1 ) (19 ) - Share-based compensation (2,456 ) (360 ) (5,137 ) (1,321 ) - Litigation provision - - (1,000 ) - - Income tax provision on pre-tax adjustments - - - - 3,486 Non-GAAP $ 92,143 $ 11,567 $ 11,890 $ 25,397 $ 7,118 Three Months Ended March 31, 2025 Selling, General Research Cost of distribution and and Income revenue and marketing administrative development tax provision GAAP $ 85,277 $ 11,866 $ 15,996 $ 20,096 $ 5,577 Intangible asset amortization (6,220 ) - (1 ) (19 ) - Share-based compensation (2,338 ) (313 ) (4,569 ) (1,173 ) - Income tax provision on pre-tax adjustments - - - - 3,047 Non-GAAP $ 76,719 $ 11,553 $ 11,426 $ 18,904 $ 8,624 SOURCE: Amphastar Pharmaceuticals, Inc. View the original press release on ACCESS Newswire